Attoquant Diagnostics

Attoquant Diagnostics is a specialized service and diagnostics company leveraging liquid chromatography-tandem mass spectrometry (LC-MS/MS) to precisely quantify peptide hormones within the Renin-Angiotensin-Aldosterone System (RAAS). Its core offerings include the RAS-Fingerprint™ for comprehensive angiotensin metabolite profiling and the RAAS Triple-A™ activity assay, providing critical tools for pharmaceutical R&D and clinical research. As a private, revenue-generating entity, it operates a fee-for-service business model supported by Austrian public grants, positioning itself as a niche expert in a complex and growing segment of cardiovascular diagnostics.

Proprietary LC-MS/MS (liquid chromatography-tandem mass spectrometry) platform for highly specific quantification of peptide hormones and enzyme activities, focused on the Renin-Angiotensin-Aldosterone System (RAAS). Core technologies include the RAS-Fingerprint™ metabolite panel and RAAS Triple-A™ enzyme activity assay.

Attoquant competes in a specialized niche. Broad-based contract research organizations (CROs) and central labs offer mass spectrometry services, but few focus exclusively on the RAAS with proprietary panels. It also competes indirectly with manufacturers of traditional immunoassays for renin and aldosterone, though its LC-MS/MS technology offers superior specificity for complex peptide profiling.